Citigroup Inc Compass Pathways PLC Transaction History

Citigroup Inc

$217 Billion
Q3 2025

A detailed history of Citigroup Inc transactions in Compass Pathways PLC stock. As of the latest transaction made, Citigroup Inc holds 1,763 shares of CMPS stock, worth $15,056. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,763

Previous 10,180 82.68%

Holding current value

$15,056

Previous $86,000 82.56%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	SELL	N/A	-8,417 Reduced 82.68%	1,763 $15,000
Q2 2025 Aug 11, 2025	BUY	N/A	9,274 Added 1023.62%	10,180 $86,000
Q1 2025 May 12, 2025	BUY	N/A	906 New	906 $7,000
Q3 2024 Nov 12, 2024	BUY	N/A	34,431 Added 176.01%	53,993 $461,000
Q2 2024 Aug 12, 2024	BUY	N/A	19,562 New	19,562 $167,000
Q4 2023 Feb 09, 2024	SELL	N/A	-5,927 Reduced 99.66%	20 $0
Q3 2023 Nov 09, 2023	BUY	N/A	5,540 Added 1361.18%	5,947 $50,000
Q2 2023 Aug 10, 2023	SELL	$7.79 - $10.69 $1,620 - $2,223	-208 Reduced 33.82%	407 $3,000
Q1 2023 May 11, 2023	BUY	$7.32 - $10.85 $2,027 - $3,005	277 Added 81.95%	615 $6,000
Q4 2022 Feb 09, 2023	BUY	$7.84 - $11.68 $133 - $198	17 Added 5.3%	338 $2,000
Q3 2022 Nov 10, 2022	SELL	$10.73 - $20.07 $858 - $1,605	-80 Reduced 19.95%	321 $3,000
Q2 2022 Aug 10, 2022	SELL	$6.76 - $14.18 $2,697 - $5,657	-399 Reduced 49.88%	401 $4,000
Q1 2022 May 12, 2022	SELL	$11.13 - $23.04 $879 - $1,820	-79 Reduced 8.99%	800 $10,000
Q4 2021 Feb 10, 2022	SELL	$21.81 - $48.96 $2,639 - $5,924	-121 Reduced 12.1%	879 $19,000
Q3 2021 Nov 10, 2021	BUY	$29.03 - $38.62 $29,030 - $38,620	1,000 New	1,000 $30,000

Others Institutions Holding CMPS

# of Institutions

177

Shares Held

55M

Call Options Held

1.86M

Put Options Held

520K

View Full List

About COMPASS Pathways plc

Ticker CMPS
Exchange NASDAQ
Sector Healthcare
Industry Medical Care Facilities
Shares Outstandng 42,522,400
Market Cap $363M
Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...

More about CMPS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account